SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending as community members highlight its strong performance, with some suggesting it's outperforming Bitcoin and has potential to reach new highs. Discussions include its upcoming anniversary, technical analysis pointing to further upside, and potential for privacy coins in the current market. Some users speculate on possible price targets and the impact of Grayscale's Zcash Trust.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

MTEX is trending due to a potential short squeeze driven by its low float and recent price volatility, attracting both bulls and shorts. Community chatter highlights anticipation for a significant price surge, with some traders eyeing specific price targets. Overall, the stock's technical setup and small float are fueling speculation and increased trading activity.

1 dog can change your life

1DOG is trending as community members highlight its meme potential and association with the Phantom Wallet. Conversations suggest many believe it could be the next big meme coin, drawing comparisons to DOGE, with users actively encouraging others to buy in and join the "pack."

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending amidst a volatile crypto market, with a sharp dip sparking debates about market manipulation and the role of large players. The community is weighing the impact of potential ETF approvals against concerns of over-leveraged positions and broader market instability. Discussions also include speculation around geopolitical factors influencing price movements and potential bottom levels.

SPDR Series Trust - SPDR S&P Aerospace & Defense ETF

SPDR S&P Aerospace & Defense ETF

The SPDR S&P Aerospace & Defense ETF ($XAR) is trending due to escalating geopolitical tensions and expectations of increased military spending, particularly following comments from European leaders and potential policy shifts in the U.S. Community discussions center on the fund's recent highs and potential breakout, while some traders discuss trimming positions after recent gains. Broader sector analysis highlights defense as a potential safe haven amid market uncertainty.

What Is Pi Network? Pi Network is a social cryptocurrency, developer platform, and ecosystem designed for widespread accessibility and real-world utility. It enables users to mine and transact Pi using a mobile-friendly interface while supporting applications built within its blockchain ecosystem.  Supply Model and Mining Mechanism The Maximum Supply of Pi is 100 billion tokens. The Maximum Supply is comprised of the following: 65 Billion tokens (or 65%) are allocated for all community mining rewards; 10 billion (10%) are allocated for foundation reserves; 5 billion (5%) are allocated for liquidity purposes; and 20 billion (20%) are allocated for the Core Team. Each allocation mentioned above tracks the community Migrated Mining Rewards issuance pace, so the proportions of each allocation in the total supply remains the same at any given time.   The Effective Total Supply of Pi—the total Pi supply at the current time—allocates Pi proportionally the same as the Maximum Supply. Since every allocation tracks the Migrated Mining Rewards of the community, the Effective Total Supply can be calculated by dividing the current Migrated Mining Rewards of Pi on the Mainnet blockchain by 65%. The other allocations within the Effective Total Supply can then be calculated based on the same proportions as the Maximum Supply, e.g. at most 10% of the Effective Total Supply is available in the foundation reserve, 5% of the Effective Total Supply is available for liquidity purposes, and 20% of the Effective Total Supply is available for the Core Team. This remains true despite the fact that all tokens were minted at the genesis as technically required by the blockchain protocol.  Circulating Supply includes all Migrated Mining Rewards and all tokens that entered circulation from other buckets of the allocations, which at its maximum could be summed up to equal the Effective Total Supply.   Pi’s mining rewards are distributed based on an issuance formula that follows a declining exponential model defined in the Pi whitepaper. Users can increase the amount of mining rewards they receive based on their individual contributions to the network, like Security Circles, using utility-based Pi apps, running Nodes, etc. For each month, the amount of Pi to be distributed as mobile balance is capped and determined by the model, regardless of how many people or how many types of mining rewards there are during the month. The capping is achieved by the design of a system-wide base mining rate, and each type of mining rewards to each individual are just a multiplier of this base mining rate. As the monthly supplies always diminish, the base mining rate generally decreases over time.   Fewer Pi may also be issued because the real Pi issuance on the blockchain depends on Pioneers passing KYC and completing all steps required for migration to the Mainnet. Despite all efforts to facilitate and remind Pioneers to complete those required steps, there are always dropoffs along the way, resulting in less than all outstanding mobile balances to be issued on the blockchain. Because of this mechanism, the community issued amount (Migrated Mining Rewards) on the blockchain will likely be closer and closer to a line lower than the 65 billion. This is thus the reason for the variable Effective Total Supply which incorporates this effect. Effective Total Supply results from all Migrated Mining Rewards divided by 65%, as opposed to the Maximum Supply of 100 billion.  Ecosystem and Adoption Pi Network has built an integrated ecosystem that facilitates real-world transactions and decentralized applications. Pi can be used as a medium of exchange for goods and services, including online commerce and local brick-and-mortar businesses.  Users can engage with Core Team and community-built apps in the Pi ecosystem through the Pi Browser, where integrated features like the Pi Wallet provide a seamless experience. Events like PiFest 2024 showcased Pi’s growing adoption, with over 27,000 active sellers and 28,000 test merchants across 160 countries.  Who Are the Founders of Pi Network? Pi Network was founded by Dr. Nicolas Kokkalis and Dr. Chengdiao Fan, both of whom have PhDs from Stanford University and a passion for improving human lives through technology.  Dr. Nicolas Kokkalis is a Stanford PhD in EE and postdoc in CS with research on distributed systems and human-computer interaction. His work focuses on combining distributed systems and human computer interaction to bring cryptocurrency to everyday people. As a strong and long-term believer of the technical, financial and social potential of cryptocurrencies, he is determined to move them beyond their current limitations and is committed to bringing the power of blockchain to more people.  Dr. Chengdiao Fan holds a Stanford PhD in Anthropological Sciences, harnessing social computing to unlock human potential on a global scale. Chengdiao is building Pi Network to mobilize individuals all over the world to participate and be rewarded for their contributions, and establish an inclusive ecosystem for global citizens to unleash and capture their own agency, and in turn create utilities and productions for society and the world.  Compliance and Identity Verification Pi Network follows a one-account-per-person policy through its Know Your Customer (KYC) solution. This system combines machine automation and human verification to authenticate user identities while preserving privacy.  The KYC process emphasizes real individuals, combats fraudulent activities and enables fair participation in the mining process of the network. Pi’s identity verification approach balances scalability, security, and accessibility, allowing millions of users worldwide to validate their accounts while maintaining regulatory compliance.

Pi Network

Pi Network is trending amidst mixed sentiment, with some community members highlighting its potential for machine-to-machine transactions, while others express concerns about its value and KYC process; discussions include predictions, mining strategies, and frustrations over exchange listings, revealing a divided community perspective on the crypto's future.

Global X Funds - Global X Defense Tech ETF

Global X Defense Tech ETF

The Global X Defense Tech ETF ($SHLD) is trending as geopolitical tensions and increased global defense spending drive interest in defense technology companies. Community discussions highlight the potential impact of international conflicts and defense agreements on the sector, with some noting significant year-to-date gains and unusual options activity. Investors are also watching how key holdings like Palantir ($PLTR) and Rheinmetall ($RNMBY) influence $SHLD's performance.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

CVS is trending due to an agreement with activist investor Glenview Capital, leading to the appointment of four new board members. Community discussion revolves around the potential impact of this deal and speculation about future strategic moves, as well as options trading strategies. Broader market factors, including Medicare Advantage plan ratings and healthcare sector performance, also influence the conversation.

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Spyre Therapeutics Inc.

Aeglea BioTherapeutics Inc

Recent analyst upgrades from BTIG and Leerink Partners, combined with positive Phase 1 trial results for TL1A antibodies, have put $SYRE in the spotlight. The community is also closely watching the DUET readout and potential M&A activity in the IBD space, with some speculating about interest from larger pharmaceutical companies. Overall, the focus is on the company's pipeline and potential for growth in the inflammatory bowel disease treatment market.

Vanguard Group, Inc. - Vanguard Extended Market Index ETF

Vanguard Extended Market ETF

The Vanguard Extended Market ETF ($VXF) is trending as traders discuss potential dip-buying opportunities in small to mid-cap stocks, particularly as the 10-year Treasury yield fluctuates around the 4.00% level. Community members are analyzing technical indicators like moving averages and LEAPS option strategies to gauge market sentiment and potential ROI. Recent alerts regarding $VXF options and discussions around the Thrift Savings Plan (TSP) S-Fund's performance are also contributing to the increased attention.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should Investors Pivot to Global Equity ETFs for Wider Market Exposure?

Investors can eye global equity funds as AI bubble fears, U.S. market risks and Fed easing fuel demand for international diversification.

Danish drugmaker Novo Nordisk (NVO) has reportedly laid off dozens of employees at its largest U.S. manufacturing site, which produces its blockbuster Semaglutide drugs.According to a Reuters <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/world-at-work/novo-nordisk-cuts-hit-production-line-jobs-key-us-plant-posts-show-2025-10-07/">report</a>, citing a review of LinkedIn posts, the job cuts included staff in manufacturing roles, from quality control to production line technicians at Novo’s major Clayton, North Carolina, plant and other facilities in the state. It also includes a strategic communications manager and an HR assistant, the report added.The Clayton facility makes Semaglutide, the active ingredient in the company’s blockbuster Wegovy and Ozempic. It also does steps including filling, finishing, and packaging the injections. It will also play a part in the production of the pill version of Wegovy once available, Reuters noted.Notably, Novo announced layoffs in September and forecast billions in annual savings. The company had said that it would cut 9,000 positions, or about 11.5% of its 78,400-strong global workforce, as part of a company-wide transformation. About 5,000 roles will be eliminated in Denmark, it said.The restructuring is expected to save eight billion Danish crowns ($1.26 billion) annually by 2026 and will focus resources on diabetes and obesity, Novo’s key growth areas. Reuters noted that the exact reason and number for layoffs in Clayton are unclear.Shares of NVO stock fell 1% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">NVO stock</a> stayed within the ‘neutral’ territory over the past 24 hours, and message volume stayed within ‘normal’ levels.<figure class="image"><img style="aspect-ratio:1364/120;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_07_at_7_12_09_AM_png_2205cacccb.webp" alt="NVO's Sentiment Meter and Message Volume as of 7:10 a.m. ET on Oct. 07, 2025 | Source: Stocktwits" width="1364" height="120"><figcaption>NVO's Sentiment Meter and Message Volume as of 7:10 a.m. ET on Oct. 07, 2025 | Source: Stocktwits</figcaption></figure>NVO stock fell 31% this year and by about 49% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/grrr-shares-rally-over-4-percent-pre-market-retail-says-stock-should-be-trading-over-40/ch6PBTQR3Wu">GRRR Shares Rally Over 4% Pre-Market, Retail Says Stock Should Be Trading Over $40: ‘Unbelievable! Way, Way Undervalued’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk Reportedly Slashes Workforce At Its US Wegovy Manufacturing Plant

According to a Reuters report, the job cuts included staff in manufacturing roles, from quality control to production line technicians at Novo’s major Clayton plant. 

Equity

According to a Reuters report, the job cuts included staff in manufacturing roles, from quality control to production line technicians at Novo’s major Clayton plant. 


Global Equity ETFs Draw Rising Investor Interest

Global equity funds saw $10.65B inflows as Fed rate cut bets, a weak dollar and diversification needs drive investors abroad.

Diversify With ETFs and Stay Ahead in Volatile Markets

Amid AI bubble worries and tech sell-offs, investors turn to value, consumer staples, gold and international ETFs for diversification.

Drugmaker Novo Nordisk (NVO) will offer a reduced 2025 yearly bonus to its employees in Denmark due to the company’s lowered forecast, Bloomberg reported on Friday, citing a company spokesperson.The reduction will apply to employees who are eligible for short-term incentives in Denmark, the report <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-08-22/novo-to-cut-employee-bonuses-in-denmark-due-to-slower-growth?srnd=homepage-americas">added</a>. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">Novo</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘normal’ levels. Shares of the company traded 3% higher in the pre-market session at the time of writing.<figure class="image"><img style="aspect-ratio:574/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_22_at_8_54_27_AM_png_454a11d7f9.webp" alt="NVO's Sentiment Meter and Message Volume as of 8:50 a.m. ET on Aug. 22, 2025 | Source: Stocktwits" width="574" height="62"><figcaption>NVO's Sentiment Meter and Message Volume as of 8:50 a.m. ET on Aug. 22, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that they expect the stock to hit $80 by the end of the year.<stembedurl>https://stocktwits.com/WallstreetPatron43/message/626170781</stembedurl>Another user said that they expect a lot of shorting on Friday.<stembedurl>https://stocktwits.com/oldmanrizzer/message/626170959</stembedurl>Earlier this week, it was <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-freezes-hiring-to-cut-costs-says-report/chsinAURdhO">reported</a> that the drugmaker has implemented a hiring freeze, which will apply across all markets and departments, with an exemption for business-critical roles. Former CEO of Novo Nordisk, Lars Fruergaard Jørgensen, said earlier this month that the company is taking measures to sharpen its commercial execution further, and ensure efficiencies in cost base while continuing to invest in future growth. Novo’s new CEO, Maziar Mike Doustdar, took charge on August 7.Last month, the company, battling competition from its U.S. rival Eli Lilly, lowered its full-year 2025 outlook, citing lower growth expectations for its blockbuster weight loss drug Wegovy and diabetes drug Ozempic for the second half of the year.The firm now expects sales growth of 8% to 14% during the year at a constant exchange rate, down from its previous estimate of 13% to 21%. Operating profit growth is now expected to be 10% to 16%, down from its prior outlook of 16% to 24%.NVO stock is down by 36% this year and by 59% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/jpmorgan-sees-near-50-percent-upside-on-ehang/chsZcIERd0M">JPMorgan Sees Near 50% Upside On This Chinese eVTOL Maker: Retail Believes There’s A Lot To Look Forward To</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Novo Nordisk To Reportedly Cut Yearly Bonus For Denmark Employees: Retail Expects Stock To Hit $80 By Year-End

According to Bloomberg, the reduction in bonuses will apply to employees who are eligible for short-term incentives in Denmark.

Retail sentiment around Anheuser-Busch InBev (ABI),&nbsp;the maker of Budweiser and Corona beers, ticked higher, even as a weak quarterly report sent its shares sliding on Thursday.<a href="https://stocktwits.com/symbol/BUD">BUD's U.S.-listed shares</a> dropped over 13%&nbsp;in the previous session, marking their worst day in over five years.On Stocktwits, retail sentiment&nbsp;shifted to 'extremely bullish' by early Friday, up from 'bullish' the day before, as traders&nbsp;viewed the slide as an overreaction and saw it as a buying opportunity. Message volume for BUD rose 1,200% in the past 24-hour period, among the highest for a consumer stock.<figure class="image"><img style="aspect-ratio:1256/156;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_01_at_12_48_05_PM_png_fd95800c98.webp" alt="Screenshot 2025-08-01 at 12.48.05 PM.png" width="1256" height="156"><figcaption>BUD sentiment and message volume as of August 1 | Source: Stocktwits</figcaption></figure>"Not a fan of the company, but this drop is a bit unjustified," said one user<stembedurl>https://stocktwits.com/Reddiot/message/623258303</stembedurl>Another said: "$BUD Buying dat dip, 10% discount? Thank you!" A third user shared a technical chart showing the stock hitting a key long-term support level.<stembedurl>https://stocktwits.com/stocksailor23/message/623228047</stembedurl><stembedurl>https://stocktwits.com/theoptionsplug/message/623173574</stembedurl>AB InBev said revenue grew 3% organically in the second quarter, below market expectations of 3.2% growth. Organic sales volumes, however, were down 1.9%,&nbsp;primarily due to weak sales in Brazil and China, marking the&nbsp;ninth consecutive quarter of declining beer sales.&nbsp;That was significantly below the 0.3% decline analysts had expected.Organic operating profit increased by 6.5%, ahead of analysts' forecasts of 5.7%.The world's largest brewer also reported weaker-than-expected volumes in Europe and the Middle East,&nbsp;which led to disappointment in all regions except North America.A rebound in the home market comes even as beer demand softens in the region. Bank of America has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bof-a-downgrades-miller-lite-brewer-molson-coors-amid-softness-in-us-beer-sales/chmZESFRReS">predicted</a> that U.S. beer volumes will shrink by 4% next year, steeper than its earlier prediction of 1% decline.In early July, AB InBev&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/budweiser-maker-ab-inbev-plans-300m-investment-to-expand-us-production/chi8fifRbZd">announced</a> plans to invest $300 million in its U.S. manufacturing operations this year, aligning with the Trump administration's broader push for domestic production.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/Starbucks-china-operations-jd-tencent-kkr-among-potential-investors/chr3YU9RdGt">Starbucks China Operations: JD, Tencent, KKR Among Potential Investors To Submit Bids - Report</a>

In this photo illustration, Budweiser beer bottles are seen displayed. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Budweiser Maker’s Stock Gets Crushed After Q2 Gloom — Retail Traders Feel 'Drop Is A Bit Unjustified'

U.S.-listed shares of the world's largest brewer marked their worst day in over five years after the company missed revenue and volume estimates.

U.S. District Judge Mark Pittman in Fort Worth, Texas, reportedly upheld the U.S. Food and Drug Administration's (FDA) decision on Wednesday to remove Novo Nordisk's popular drugs, Ozempic and Wegovy, from its shortage list.Pittman said that the FDA had appropriately weighed supply and demand data for the drugs and properly removed them from the shortage list while rejecting a challenge brought by compounding pharmacies who sought to continue making copies of the drugs, Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-judge-upholds-fdas-removal-ozempic-wegovy-drug-shortage-list-2025-06-18/">reported</a>.Compounders are allowed to produce copies of drugs only when they are declared to be in short supply by the FDA. In February, the FDA announced that the semaglutide injection product shortage had been resolved, preventing compounders from manufacturing copies of Wegovy and Ozempic, as semaglutide is the active ingredient in them.Semaglutide injection products were first added to the FDA’s drug shortage list in 2022, paving the way for compounders to replicate them.Late last month, Novo Nordisk said that it had filed nearly 120 lawsuits across 34 states against compounders and other entities making false and misleading claims about their “semaglutide" drugs.The company also announced a $199-per-month limited-time offer for self-paying patients new to its weight loss drug, Wegovy, to encourage patients who previously used compounded versions of the drug to transition to Wegovy.On Stocktwits, retail sentiment around Novo Nordisk shares rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume fell from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:629/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_18_at_12_40_07_PM_png_8852be04e7.webp" alt="NVO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on June 18, 2025 | Source: Stocktwits" width="629" height="65"><figcaption>NVO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on June 18, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down by about 15% this year and by about 47% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tmc-stock-surges-to-near-4-year-high-after-opening-the-door-to-cashless-exercise-of-class-b-warrants/chlsB67RR2h">TMC Stock Surges To Near 4-Year High After Opening The Door To Cashless Exercise Of Class B Warrants</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

US Judge Upholds FDA Decision To Remove Wegovy, Ozempic From Shortage List In Move Against Compounding Pharmacies

The judge said that the FDA had appropriately weighed supply and demand data for the drugs and properly removed them from the shortage list, Reuters reported. 

Danish drugmaker Novo Nordisk (NVO) <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916348">announced</a> on Thursday that it plans to initiate a late-stage development program with its experimental drug Amycretin for adults with obesity or those who are overweight, starting in the first quarter of 2026.Shares of NVO traded 3% higher on Thursday.The decision to advance the study of Amycretin into the late stage is based on feedback received from regulators following mid-stage studies.Amycretin is a single molecule that operates as both GLP-1 receptor agonist and amylin receptor agonist.While GLP-1 receptor agonists work by mimicking the natural hormone GLP-1, Amylin receptor agonists mimic the effects of the natural hormone amylin, reducing appetite. The drug is developed for subcutaneous and oral administration.The company’s popular weight-loss drug Wegovy’s active component is Semaglutide, another GLP-1 receptor agonist.In the first quarter, Wegovy experienced an 85% increase in sales to DKK 17.36 billion ($2.69 billion), while the company’s overall sales within its obesity care segment grew 67% to DKK 18.42 billion.However, last month, the company said that Lars Fruergaard Jørgensen will <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-ceo-to-step-down/chiw5m5Rbno">step down</a> as CEO as per a mutual agreement with the Novo Nordisk board.The board stated that the change is being made in light of Novo Nordisk's recent market challenges, the company’s declining share price since mid-2024, and discussions with the Novo Nordisk Foundation.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> has fallen by about 8% this year and by about 44% over the past 12 months.On Stocktwits, retail sentiment around Novo Nordisk stayed unmoved within the ‘bullish’ territory over the past 24 hours while message volume remained ‘high’.<figure class="image"><img style="aspect-ratio:628/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_12_at_2_12_25_PM_png_81063cab85.webp" alt="Screenshot 2025-06-12 at 2.12.25 PM.png" width="628" height="64"><figcaption>NVO's Sentiment Meter and Message Volume as of 2:10 p.m. ET on Jun 12, 2025 | Source: Stocktwits</figcaption></figure>Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/google-cloud-teams-up-with-databricks-to-scale-gemini-enterprise-adoption/chlgdNHRRGd">Google Cloud Teams Up With Databricks To Scale Gemini Enterprise Adoption</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.(Exchange Rate: 1 DKK= 0.16 USD)

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk’s Plan To Start Late-Stage Trial Of Investigational Obesity Drug Amycretin In 2026 Gets Retail Talking

The decision to advance the study of subcutaneous and oral Amycretin into the late stage is based on feedback received from regulators following mid-stage studies.

Denmark-headquartered Novo Nordisk (NVO) has <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/deep-apple-therapeutics-announces-collaboration-with-novo-nordisk-to-discover-and-develop-oral-therapeutics-for-cardiometabolic-diseases-302478417.html">entered</a> into a collaboration and exclusive worldwide license agreement with California-based Deep Apple Therapeutics, Inc. to develop drugs for cardiometabolic diseases, including obesity.Under the terms of the deal, valued at up to $812 million, Deep Apple will discover oral therapies using its AI-based drug discovery platform, and Novo Nordisk will receive exclusive global rights to develop, manufacture, and commercialize the resulting compounds and products in all indications.Both companies will collaborate on the research plan, Deep Apple said.Deep Apple is eligible to receive an upfront payment, research costs, and milestone payments from Novo Nordisk. In total, Deep Apple will be eligible to receive up to $812 million in payments, as well as potential royalties on sales of any products that emerge from the collaboration.Last month, Novo also announced a similar exclusive global collaboration and license agreement with U.S.-based Septerna, Inc. (SEPN) to discover, develop, and commercialize oral small-molecule medicines for obesity, type 2 diabetes, and other cardiometabolic diseases. The company said the deal could be worth up to $2.2 billion.Separately, chipmaker Nvidia (NVDA) <a target="_blank" rel="noopener noreferrer nofollow" href="https://nvidianews.nvidia.com/news/nvidia-partners-with-novo-nordisk-and-dcai-to-advance-drug-discovery">announced</a> a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases.The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development.“By coupling NVIDIA’s accelerated computing platform and expertise with Novo’s deep expertise in life sciences research and development, we aim to build custom models that will aid our scientists in developing new medicines faster and more efficiently,” said Mishal Patel, senior vice president, AI and digital innovation at Novo Nordisk.On Stocktwits, retail sentiment around Novo Nordisk jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_11_at_10_20_55_AM_png_f4ab145e9d.webp" alt="NVO's Sentiment Meter and Message Volume as of 10:20 a.m. ET on Jun 11, 2025 | Source: Stocktwits" width="625" height="65"><figcaption>NVO's Sentiment Meter and Message Volume as of 10:20 a.m. ET on Jun 11, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down by about 9% this year and about 44% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/jd-vance-slams-fed-for-not-cutting-rates-post-inflation-report/chlaMlyRbCt">JD Vance Slams Fed For Not Cutting Rates Post Inflation Report, Says Refusal By The Central Bank Is ‘Monetary Malpractice’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Novo Nordisk’s $812M Deal With Deep Apple Lifts Retail Mood, Chatter Spikes To High Levels

Separately, chip-maker Nvidia also announced a collaboration with Novo Nordisk to accelerate drug discovery efforts through innovative AI use cases.

Toyota Industries is expected to announce that it will accept a takeover bid from Toyota Motor Corp. (TM) and other group companies as early as Tuesday, Nikkei Asia <a target="_blank" rel="noopener noreferrer nofollow" href="https://asia.nikkei.com/Business/Business-deals/Toyota-Industries-to-announce-acceptance-of-42bn-takeover-bid">reported</a> on Monday.The consortium is expected to take Toyota Industries private after the firm accepts the tender offer, the report added. The takeover bid is estimated to be 6 trillion yen, or approximately $42 billion.Toyota Industries develops and manufactures automobiles and automobile-related products, such as vehicles, engines, car air-conditioning compressors, car electronics components and devices, and stamping dies. It also develops and produces the RAV4 for Toyota Motor.The companies maintained a close relationship after Toyota Motor was spun off from Toyota Industries in 1937.In FY2024, net sales to Toyota Motor accounted for 12.8% of Toyota Industries’ consolidated net sales. As of March 31, 2024, TMC also held 24.7% of Toyota Industries’ voting rights.The carmaker had said in April that it is exploring investing in the potential buyout of its supplier.Toyota is the largest automaker in the world in terms of global sales. In 2024 alone, the company sold 10.8 million vehicles.Last month, the company also said that its worldwide sales and production rose for the fourth consecutive month in April.The company’s global sales jumped 10% to 876,864 units in April on the back of a near 12% jump in sales within Japan and a near 10% increase in sales outside the home country.On Stocktwits, retail investor sentiment about Toyota remained unmoved within the ‘bearish’ territory over the past 24 hours while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:636/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_02_at_1_30_22_PM_png_979a999514.webp" alt="TM's Sentiment Meter and Message Volume as of 1:30 p.m. ET on June 2, 2025 | Source: Stocktwits" width="636" height="67"><figcaption>TM's Sentiment Meter and Message Volume as of 1:30 p.m. ET on June 2, 2025 | Source: Stocktwits</figcaption></figure> NYSE-listed shares of <a href="https://stocktwits.com/symbol/TM/sentiment">Toyota</a> traded over 1% lower on Monday. The stock is down by about 3% this year and by over 11% over the past 12 months.&nbsp;Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/muln-automotive-raises-stake-in-bollinger-motors/chkYEF6RbHg">Mullen Automotive Raises Stake In Bollinger Motors To 95%, Trading Activity Halts As Stock Undergoes Reverse Split</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Raindrops are seen on Toyota car logo in Krakow, Poland on December 23, 2024. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Toyota Industries Likely To Accept $42B Takeover Bid From Toyota Motor And Group Companies, Says Report: Retail’s Undecided

The consortium is expected to take Toyota Industries private after it accepts the tender offer, with the takeover bid estimated at 6 trillion yen, or approximately $42 billion.

American Century ETF Trust - Avantis International Equity ETF

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$62.87
Prev Close	$62.48
Open	$62.77
Dividend Yield	N/A
50-Day Moving Average	$62.33
Beta	N/A
Avg. Volume	297,038.25
PE Ratio	N/A

52-Week High	$64.17
52-Week Low	$52.86
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

AVDE
American Century ETF Trust - Avantis International Equity ETF

Feed

News

Sentiment

Fundamentals

Info

Latest AVDE News

AVDEAmerican Century ETF Trust - Avantis International Equity ETF